BioLineRX Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
IL0011015182
Biotechnology & Medical Research
Sales 2024 * | 14.36M 5.34B | Sales 2025 * | 27.77M 10.32B | Capitalization | 48.58M 18.06B |
---|---|---|---|---|---|
Net income 2024 * | -47M -17.47B | Net income 2025 * | -36M -13.38B | EV / Sales 2024 * | 3.38 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.75 x |
P/E ratio 2024 * |
-2.03
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRX Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
1st Jan change | Capi. | |
---|---|---|
-1.65% | 103B | |
+6.75% | 101B | |
+5.71% | 23.07B | |
-12.60% | 22.23B | |
-9.70% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |